LEADER 03711nam 2200721 450 001 9910145809003321 005 20220805214159.0 010 $a1-283-51409-5 010 $a9786613826541 010 $a1-4443-0020-2 010 $a1-4443-0021-0 035 $a(CKB)1000000000715925 035 $a(EBL)416368 035 $a(OCoLC)476247545 035 $a(SSID)ssj0000112114 035 $a(PQKBManifestationID)11819483 035 $a(PQKBTitleCode)TC0000112114 035 $a(PQKBWorkID)10081240 035 $a(PQKB)10357910 035 $a(MiAaPQ)EBC416368 035 $a(EXLCZ)991000000000715925 100 $a20160805h20082008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aBiomarkers in heart disease /$fedited by James A. de Lemos 210 1$aMalden, Massachusetts :$cBlackwell Publishing,$d2008. 210 4$dİ2008 215 $a1 online resource (252 p.) 225 1 $aAHA Clinical Series 300 $a"American Heart Association." 311 $a1-4051-7571-0 320 $aIncludes bibliographical references and index. 327 $aContents; Contributors; Preface; Foreword; PART I Biomarkers for the Evaluation of Patients with Ischemic Heart Disease; 1 Protocols for diagnosing myocardial infarction; 2 Troponin and other markers of necrosis for risk stratification in patients with acute coronary syndromes; 3 Challenges interpreting cardiac troponin values; 4 Natriuretic peptides and inflammatory markers for risk stratification in patients with ischemic heart disease; 5 Novel markers in patients with suspected acute coronary syndromes; PART I I Biomarkers for Evaluation of Patients with Heart Failure 327 $a6 Use of natriuretic peptides in the diagnosis of heart failure7 Biomarkers for risk stratification in patients with heart failure; 8 Natriuretic peptides for disease monitoring in patients with chronic heart failure; PART I I I Biomarkers for Screening in Ambulatory Populations; 9 C-Reactive Protein; 10 Newer markers for population screening: focus on lipoprotein-related markers; PART I V A Look to the Future; 11 Moving toward personalized medicine; Index 330 $aBiomarkers in Heart Disease is the first title in the AHA Clinical Series and is aimed at meeting the needs of clinicians, providing cardiologists, internists, emergency physicians, laboratorians, and other healthcare providers with a clear understanding of the role of biomarkers in contemporary cardiovascular medicine. The book covers both the strengths and pitfalls of currently available markers, and provides information on the most promising biomarkers that are likely to impact practice in the next few years. It is divided into four parts, organized around clinical scena 410 0$aAHA clinical series. 606 $aDiseases$xRisk factors$vMethods 606 $aBiochemical markers 606 $aHeart$xDiseases$xDiagnosis 606 $aHeart$xDiseases 606 $aHeart$xDiseases$xMolecular diagnosis 606 $aBiochemical markers$xDiagnostic use 608 $aElectronic books. 615 0$aDiseases$xRisk factors 615 0$aBiochemical markers. 615 0$aHeart$xDiseases$xDiagnosis. 615 0$aHeart$xDiseases. 615 0$aHeart$xDiseases$xMolecular diagnosis. 615 0$aBiochemical markers$xDiagnostic use. 676 $a616.1/2075 676 $a616.12075 702 $ade Lemos$b James 712 02$aAmerican Heart Association. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910145809003321 996 $aBiomarkers in heart disease$92186530 997 $aUNINA